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Background: Polycomb group genes (PcGs) are epigenetic effectors implicated in most cancer hallmarks. The mutational status
of all PcGs has never been systematically assessed in solid tumours.
Methods: We conducted a multi-step analysis on publically available databases and patient samples to identify somatic
aberrations of PcGs.
Results: Data from more than 1000 cancer patients show for the first time that the PcG member PHC3 is amplified in three
epithelial neoplasms (rate: 8–35%). This aberration predicts poorer prognosis in lung and uterine carcinomas (Po0.01). Gene
amplification correlates with mRNA overexpression (Po0.01), suggesting a functional role of this aberration.
Conclusion: PHC3 amplification may emerge as a biomarker and potential therapeutic target in a relevant fraction of epithelial
tumours.
Epigenetic aberrations have been widely reported in human
neoplasms, and preclinical studies have established conclusive
links between epigenetics and most cancer hallmarks (Baylin and
Jones, 2011). Despite this, the only epigenetic drugs approved for
clinical use are DNA-methyltransferase and histone-deacetylase
inhibitors, whose employment is restricted to a few haematological
malignancies (Piekarz and Bates, 2009). Even the clinical
exploitation of epigenetic biomarkers as prognostic/predictive
factors is currently limited to a few notable exceptions (Wick
et al, 2009).
Polycomb group genes (PcGs) are epigenetic effectors organised
into two main repressive complexes (PRC1, PRC2). The PRCs
silence tumour-suppressor genes through histone modifications,
thereby driving cancer cell proliferation, metastasis and drug
resistance (Crea et al, 2012). Despite a plethora of preclinical
studies demonstrating their crucial role in human neoplasms, PcGs
still lack clinical value. Most molecular research has focused on the
histone-methyltransferase EZH2 (PRC2 member), which acts as an
oncogene in several neoplasms (Chase and Cross, 2011). To the
contrary, the role of PRC1 in many solid tumours is still largely
overlooked.
The recent identification of EZH2-specific inhibitors has been
welcomed as a fundamental advancement in epigenetic therapy
(Melnick, 2012). Those molecules are particularly effective on
lymphoma cells harbouring EZH2-activating mutations, but not on
cells with simple mRNA upregulation (McCabe et al, 2012).
In addition, inhibition of the catalytic subunit of PRC1 induces
cancer cell apoptosis (Wen et al, 2013), thereby paving the way for
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the development of PRC1-targeting drugs. As PcG mutations have
been described almost exclusively in haematological malignancies
(Chase and Cross, 2011), there is currently no genetic evidence to
predict their efficacy in solid tumours. Most reports on PcG status
in solid neoplasms are restricted to gene expression analysis of a
few popular targets (EZH2, BMI1), overlooking the evidence that
human PcGs are encoded by least 18 different genes
(Christophersen and Helin, 2010), and not taking into account
possible mutational events. For this reason, we explored publically
available databases and patient data sets to investigate the
mutational status and clinical significance of all PcGs in solid
tumours.
METHODS
We conducted a two-step analysis on publically available databases.
First, we queried the cBio database for somatic aberrations (gene
amplification, insertion, deletion, point mutation) in each PcG
(listed in Christophersen and Helin (2010), Supplementary
Table 1). This database includes mutational data from exome
sequencing, copy number calls from GISTC 2.0, and for some
studies, mRNA levels expressed as Z score from RNA seq (Cerami
et al, 2012). The cBio portal provides access to more than 5000
samples from over 20 cancer studies. Herein we report results only
for those genes showing a mutational rate higher than 5%. We
restricted our analysis to studies available for publication (bladder,
breast, ovarian, glioblastoma, lung, prostate, and uterine carcinomas).
To confirm our findings in an independent data set, we selected the
most frequently mutated gene (PHC3), and investigated its clinical
relevance in both cBio and Oncomine (Rhodes et al, 2007) databases
(more than 100 additional data sets, more than 10 000 patients
screened), searching for correlations between gene expression/
amplification and clinico/pathological characteristics in lung, uterine
and ovarian neoplsams. To further reduce the false discovery rate,
we considered significant results with P-valueo0.01 and
fold-change 42.0. Amplification and overexpression of PHC3 in
lung cancer was assessed in an additional data set comprised
of 169 lung adenocarcinoma (AC) and 92 lung SCC samples, of
which 35 AC and 13 SCC tumours had patient-matched normal
tissue (GSE31800) (Starczynowski et al, 2011).
RESULTS
Our global mutational analysis is summarised in Figure 1A. We
found no relevant deletions and only two missense mutations with
a frequency higher than 5%. To the contrary, several loci were
amplified in at least one investigated neoplasm. According to
previous reports (Chase and Cross, 2011), EZH2 is not mutated in
most common solid tumours, although we found an interesting
rate of EZH2 amplification (5.6%) in ovarian serous carcinoma.
This neoplasm shows relevant amplification of four different PcGs.
Gene amplification was significantly correlated with higher mRNA
levels (Supplementary Figure 1), thereby suggesting that these
epigenetic effectors are crucial for its development.
The most striking result arising from our query was the high
rate of PHC3 genetic amplifications. This aberration was found in
lung (34.8%), ovarian (20.6%), and uterine ACs (7.7%). In order to
explore the functional role of this genetic aberration, we computed
the correlation between gene amplification and mRNA upregula-
tion in those three neoplasms. Notably, gene amplification was
significantly correlated with mRNA upregulation in each tumour
type (Figure 1B–D).
Oncomine data confirmed that PHC3 is selectively upregulated
in SCC, compared with other non-small-cell lung cancer subtypes
(Figure 2A, P¼ 1.32E 11, fold-change¼ 2.137). Furthermore,
PHC3 overexpression was found to be associated with shorter
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Figure 1. Somatic aberrations of Polycomb genes in solid tumours. (A) Somatic aberration rate in different tumour types. All displayed
percentages refer to genomic amplification, except the last two columns (EZH2_mut and PHC3_mut), which refer to missense mutation. The
mutation rate was derived from the cBio portal studies. If not specified, cancer type is adenocarcinoma. SCC¼ squamous cell carcinoma. Patient
sample size (tumours with complete information): bladder, 58; breast, 463; glioblastoma, 91; ovarian, 316; lung SCC, 178; prostate, 85; uterine
corpus, 232. If two studies with partially overlapping patient sets were present in the database, we present the published rather than the
‘provisional’ data set. (B–D) Correlation between genomic amplification and mRNA levels in different neoplasms. Black and grey rectangles refer
to the percentage of samples showing upregulated and non-upregulated Phc3 mRNA, respectively. Gene is considered upregulated when Z score
is 41.0. **Po0.001, ***Po0.0001 (Fisher exact test).
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3-year survival rate in lung cancer (Figure 2B, P¼ 0.005, fold-
change¼ 2.267, Oncomine analysis). PHC3 mRNA was also
upregulated in cervical, colorectal, gastric, and prostate ACs,
compared with normal tissues (Po0.01, fold-change 42.0,
Oncomine data not shown).
PHC3 is located at 3q62.2, a genomic region that has been
described as amplified in solid tumours (Lavigne et al, 2004;
Linxweiler et al, 2012). For this reason, we investigated amplifica-
tion and expression level of eight genes flanking the PHC3 locus
(Figure 2C). The rate of genomic amplification was very similar for
all eight genes (34–35% in lung cancer, data not shown). However,
only two genes (PHC3 and PRKCI) showed mRNA upregulation in
more than 50% of tumours with genomic amplification, suggesting
that the genetic aberration has a functional role in those loci.
The remaining six genes showed an mRNA upregulation rate lower
than 35%, even in the presence of an amplified gene.
We confirmed the high frequency of PHC3 amplification and
overexpression in lung SCC using an additional publically available
data set of 169 AC and 92 SCC tumours. PHC3 was amplified in 71
out of 92 (77%) lung SCC samples and 36 out of 169 (21%) AC and
overexpressed in 7 of 13 (54%) and 5 of 35 (14%) SCC and AC
cases, respectively. Moreover, comparison of mRNA expression
levels between AC and SCC revealed no difference in PHC3 mRNA
levels in non-malignant tissue (Figure 2D, P¼ 0.76), but
significantly higher expression in SCC tumours relative to AC
tumours (Figure 2E, P¼ 0.002) and SCC tumours relative to
matched non-malignant tissue (Figure 2F, P¼ 0.0024).
A very interesting clinical correlation was identified in uterine
carcinoma. In this neoplasm, PHC3 amplification also predicted
shorter disease-free survival (Supplementary Figure 2). Notably,
PHC3 amplification was detectable only in grade 3 neoplasms.
Despite this, our analysis indicates that PhC3 amplification is an
independent prognostic factor, even when contrasted with tumour
grade (Table 1). To the contrary, PhC3 amplification was
not significantly associated with prognosis in ovarian cancer
(Supplementary Figure 3).
DISCUSSION
Taken together, our analyses of data from three different data sets
indicate that the PHC3 gene is amplified in three epithelial
tumours, with percentages ranging from 8 to 35%. Gene
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Figure 2. PHC3 gene expression and amplification in lung cancers. (A) Correlation between PhC3 mRNA level and lung cancer histotype
(138 patients from ‘Lee Lung’ study). (B) Correlation between PhC3 mRNA level and 3-year survival in lung cancer (nine patients from ‘TCGA Lung’
study). (C) Correlation between genomic amplification and mRNA levels in PHC3 and eight additional genes located at 3q62.2 (4 next to the 50 end
and 4 next to the 30 end of the PHC3 locus, displayed from 50 to 30). The mRNA is considered upregulated when Z score is X1.0. Data are from
Cbio lung SCC data set. (D–F) Data from matched normal and neoplastic lung tissues. AC¼ adenocarcinoma (35 samples). SqCC¼ lung squamous
cell carcinoma (13 samples). Data from A and C: Oncomine (Compendia Bioscience, Ann Arbor, MI) was used for analysis and visualisation.
**Po0.01 (A and B, Oncomine analysis; D–F, two-sided t-test).
Table 1. Multi-parametric analysis of PHC3 amplification (uterine
carcinoma)
Parameter P-value Odds ratio (95% CI)
PHC3 status
Non-amplified
Amplified 0.0157 4.0 (1.3–12.3)
Grade
1
2 0.99 NC
3 0.99 NC
Abbreviations: CI¼ confidence interval; NC¼ not computable. Cox regression analysis was
performed to determine whether PhC3 mutational status was an independent predictor of
progression-free survival.
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amplification is highly correlated with mRNA overexpression and,
at least for lung and uterine cancer, associated with poorer
prognosis. PHC3 is rarely deleted and almost never downregulated
in cancer vs normal tissue. Oncomine analysis revealed that cancer-
specific PHC3 upregulation might be a common phenomenon in
several epithelial neoplasms. To the best of our knowledge, PHC3
genomic amplification and mRNA upregulation have never
been described before. However, PHC3 has been found to be
downregulated in human sarcomas, where it acts as a tumour
suppressor (Deshpande et al, 2007).
PHC3 is a member of PRC1, which catalyses histone H2A
ubiquitination. PRC1 is composed of RING1B (catalytic subunit)
and other proteins responsible for interactions with transcription
factors, epigenetic regulators, and DNA sequences. PhC proteins
bridge distant chromatin templates, thereby recruiting PRC1 to
selected loci (Lavigne et al, 2004). Currently, three PhC isoforms
are known, with different tissue distribution and partially
overlapping functions (Deshpande et al, 2007). PRC1 has been
implicated in tumorigenesis and progression of several cancer
types. Tobacco smoke is able to activate PRC1 genes, thereby
increasing the tumorigenicity of lung cancer cells (Hussain et al,
2009). Amplification of the chromosomal region harbouring the
PHC3 locus (3q26) has been described in preneoplastic and
invasive lung SCC, and its rate increases with disease progression
(Pelosi et al, 2007). Future molecular studies should dissect the role
of PHC3 in lung tumorigenicity.
As genomic amplification can occur at a multigenic scale, we
investigated if PHC3 copy number gain was associated with
similar alteration in nearby loci. Our results indicate that the
PHC3-proximity region is frequently amplified in solid tumours.
However, when we contrasted mRNA expression with genomic
amplification, we observed that only PHC3 and PRKCI mRNA
levels were frequently upregulated in tumours with copy number
gain (Figure 2D). The remaining six genes did not show
a correlation between copy number gain and increased gene
expression. Interestingly, PRKCI (protein kinase C iota) has been
described as a potential oncogene in lung cancer (Regala et al,
2009; Linxweiler et al, 2012). Our data indicate that copy number
gain may have a functional role in the PHC3 locus too, and that
PHC3 upregulation is functionally relevant for cancer cells. In
conclusion, we identified for the first time that PHC3 copy number
gain as a novel and possibly clinically significant genetic alteration
in three common epithelial neoplasms (lung SCC, uterine
carcinoma, and ovarian serous carcinoma). Future molecular
studies should dissect the role of PHC3 in each specific context.
However, our data indicate that PHC3 may emerge as a novel
oncogene, and possibly a prognostic marker and a target for
epigenetic therapy, in epithelial neoplasms.
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